[February 11, 2016]

Leishmaniasis (Kala-Azar) - Global API Manufacturers, Marketed and Phase III Drugs Landscape 2016 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/9kgzzb/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.

Leishmaniasis Kala-Azar - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Leishmaniasis Kala-Azar Report is to understand the market and pipeline status of the drugs around the Leishmaniasis Kala-Azar to explore te generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The report provides the historical and forecasted sales of the drugs till 2018.

The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Leishmaniasis Kala-Azar market while the leading brands, companies and chemicals are considered thoroughly.

The Report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Leishmaniasis Kala-Azar

7. Phase III Drugs for Leishmaniasis Kala-Azar

8. Discontinued Drugs for Leishmaniasis Kala-Azar

9. Appendix

For more information visit http://www.researchandmarkets.com/research/9kgzzb/leishmaniasis

View source version on businesswire.com: http://www.businesswire.com/news/home/20160211005735/en/

[ Back To TMCnet.com's Homepage ]